These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 25874450)
1. Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. Tang LQ; Hu DP; Chen QY; Zhang L; Lai XP; He Y; Xu YX; Wen SH; Peng YT; Chen WH; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mai HQ PLoS One; 2015; 10(4):e0122965. PubMed ID: 25874450 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era. Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482 [TBL] [Abstract][Full Text] [Related]
3. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900 [TBL] [Abstract][Full Text] [Related]
4. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma. Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025 [TBL] [Abstract][Full Text] [Related]
5. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755 [TBL] [Abstract][Full Text] [Related]
6. Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study. Chen QY; Guo SY; Tang LQ; Lu TY; Chen BL; Zhong QY; Zou MS; Tang QN; Chen WH; Guo SS; Liu LT; Li Y; Guo L; Mo HY; Sun R; Luo DH; Zhao C; Cao KJ; Qian CN; Guo X; Zeng MS; Mai HQ Cancer Res Treat; 2018 Jul; 50(3):861-871. PubMed ID: 28903550 [TBL] [Abstract][Full Text] [Related]
7. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era. Li PJ; Mo HY; Luo DH; Hu WH; Jin T Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326 [TBL] [Abstract][Full Text] [Related]
8. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. Liu LT; Tang LQ; Chen QY; Zhang L; Guo SS; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):862-9. PubMed ID: 26530755 [TBL] [Abstract][Full Text] [Related]
9. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis. Luo Y; Qin Y; Lang J Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153 [TBL] [Abstract][Full Text] [Related]
10. Elevated plasma fibrinogen level shows superior prognostic value than Epstein-Barr virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. Lan M; Chen C; Huang Y; Mao M; Han F; Liao J; Deng M; Duan Z; Zheng L; Wu S; Lu T; Jian Y Oncotarget; 2016 Jul; 7(29):46242-46252. PubMed ID: 27323828 [TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073 [TBL] [Abstract][Full Text] [Related]
12. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study. Tang LQ; Li CF; Chen QY; Zhang L; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Chen WH; Liu H; Guo SS; Liu LT; Li J; Zhang JP; Guo L; Zhao C; Cao KJ; Qian CN; Zeng YX; Guo X; Mai HQ; Zeng MS Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):325-36. PubMed ID: 25482300 [TBL] [Abstract][Full Text] [Related]
13. Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study. Lv JW; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Guo R; Lin AH; Ma J; Sun Y Oncotarget; 2016 Mar; 7(13):16806-17. PubMed ID: 26919237 [TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up. Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726 [TBL] [Abstract][Full Text] [Related]
15. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy. Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Cavernous Sinus Invasion in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy. Liao JF; Ma L; Du XJ; Lan M; Guo Y; Zheng L; Xia YF; Luo W PLoS One; 2016; 11(1):e0146787. PubMed ID: 26824230 [TBL] [Abstract][Full Text] [Related]
17. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort. Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417 [TBL] [Abstract][Full Text] [Related]
18. Clinical Outcome and Prognostic Factors of Intensity-Modulated Radiotherapy for T4 Stage Nasopharyngeal Carcinoma. Luo Y; Gao Y; Yang G; Lang J Biomed Res Int; 2016; 2016():4398498. PubMed ID: 27195286 [TBL] [Abstract][Full Text] [Related]
19. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study. Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364 [TBL] [Abstract][Full Text] [Related]
20. Investigation of long-term survival outcomes and failure patterns of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: a retrospective analysis. Zhao W; Lei H; Zhu X; Li L; Qu S; Liang X Oncotarget; 2016 Dec; 7(52):86914-86925. PubMed ID: 27894100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]